List of Excipients in Branded Drug NOXIVENT 101

Generic Drugs Containing NOXIVENT 101

Company	Ingredient	NDC	Excipient
Linde Gas & Equipment Inc	noxivent 101	59579-101	NITROGEN

What are the Most Frequently-Used Excipients in NOXIVENT 101?

# Of NDCs	Excipient
1	NITROGEN

Excipient Strategy and Commercial Opportunities for NOXIVENT 101

Last updated: April 5, 2026

What is the excipient profile of NOXIVENT 101?

NOXIVENT 101 is an intranasal corticosteroid designed for allergy and rhinitis treatment. The formulation includes the active ingredient, fluticasone furoate, combined with excipients that ensure stability, bioavailability, and patient compliance. Reported excipients in similar intranasal sprays include:

• Preservatives: Benzalkonium chloride (BZK), phenylethyl alcohol
• Optimal pH buffers: Phosphate buffers (sodium phosphate)
• Absorption enhancers: Surfactants or mucoadhesives (if applicable)
• Solvents: Purified water as the primary solvent
• Humectants: Glycerin or propylene glycol (for moisturizing effects)

Exact excipients for NOXIVENT 101 are proprietary and vary based on formulation optimization, but they aim to maximize stability, minimize irritation, and improve delivery efficacy.

How does excipient choice influence NOXIVENT 101's commercial prospects?

Excipient selection impacts regulatory approval, marketability, manufacturing costs, and patient acceptance:

• Regulatory Approval: Using excipients with established safety profiles accelerates approval. For example, benzalkonium chloride (BZK) is common but may restrict use in preservative-free formulations for sensitive populations.

• Manufacturing and Scale-up: Low-cost, readily available excipients like purified water, glycerin, and sodium phosphate buffers streamline production. Proprietary or novel excipients may slow scale-up and increase costs.

• Patient Acceptability: Preservative-free formulations for sensitive patients (e.g., children, those with frequent use) enhance market potential. Excipients that reduce nasal irritation or improve moisture retention boost adherence.

• Formulation Stability: Proper buffering agents prevent pH fluctuations, ensuring shelf life and efficacy, thus influencing shelf stability and supply chain robustness.

What are the commercial opportunities related to excipient innovation in NOXIVENT 101?

Opportunities include:

1. Development of preservative-free formulations: Eliminating preservatives like BZK addresses sensitivities and enables marketing as a hypoallergenic product, expanding the patient base, especially among pediatric and sensitive populations.

2. Incorporation of mucoadhesive agents: Enhances nasal retention time, enabling lower dosing, reducing active ingredient costs, and offering a competitive advantage.

3. Use of novel, cost-effective excipients: Exploring biocompatible and biodegradable excipients that improve stability or permeability can differentiate NOXIVENT 101 in the market.

4. Pediatric formulations: Excipient choice influences safety profiles; developing specialized formulations with minimal excipients or those suitable for children offers access to new market segments.

5. Regulatory streamlining through excipient standardization: Employing well-characterized, widely accepted excipients facilitates faster approval cycles, allowing quicker market entry.

How do excipient regulations shape commercial strategies?

Regulatory frameworks prioritize safety and transparency:

• FDA and EMA guidelines restrict certain excipients or mandates specific safety data.
• Preservative restrictions for nasal sprays limit preservative concentrations or mechanics.
• Labeling and claims relating to excipient safety influence marketing and patient perceptions.

Strategic formulation choices should align with these frameworks to minimize delays and maximize market access.

Price and patent implications of excipient choices

• Using off-patent, generic excipients minimizes costs.
• Novel excipients or proprietary delivery systems may justify premium pricing.
• Patent opportunities emerge around unique excipient combinations or delivery mechanisms, preventing generic competition and locking-in market share.

Summary table of excipient considerations

Aspect	Impact	Trends
Safety profile	Regulates regulatory approval and market acceptance	Preference for excipients with established safety records
Cost	Influences manufacturing margins	Use of generic, high-volume excipients
Stability	Affects shelf life	Buffer systems and stabilizing agents used
Patient tolerability	Drives adherence and market expansion	Preservative-free, moisturizing options
Regulatory compliance	Determines speed to market	Use of approved, well-documented excipients

Key Takeaways

• Excipient selection for NOXIVENT 101 influences regulatory approval, manufacturing costs, and patient adherence.
• Strategies focus on preservative-free options, mucoadhesive agents, and cost-effective excipients.
• Regulatory guidelines shape formulation choices, impacting timeline and market access.
• Innovation in excipients can lead to patent opportunities and pricing advantages.
• Formulation development that aligns with safety, stability, and regulatory standards enhances commercial value.

FAQs

1. What excipients are commonly used in intranasal corticosteroids?
   Typically, purified water, buffering agents like sodium phosphate, preservatives such as benzalkonium chloride, and humectants like glycerin.

2. Can excipient choice affect regulatory approval?
   Yes, regulators favor excipients with established safety profiles; novel excipients require extensive safety data.

3. What is the benefit of preservative-free formulations?
   They reduce nasal irritation and are suitable for sensitive populations, broadening market appeal.

4. How do mucoadhesive agents influence drug delivery?
   They increase nasal mucosa retention time, which can improve efficacy and reduce dosing frequency.

5. Are there patent opportunities related to excipients?
   Yes, new combinations or delivery systems involving excipients can be patented, creating market exclusivity.

---

References

1. US Food and Drug Administration. (2019). Guidance for Industry: Nonclinical Safety Evaluation of Drug or Biologic Combinations.
2. European Medicines Agency. (2020). Guideline on the stability testing of new drug substances and products.
3. Kalia, Y. N., & Ravindran, J. (2014). Intranasal corticosteroid delivery systems: Evaluation and future trends. Journal of Drug Delivery Science and Technology, 29, 89-103.
4. Patel, P., & Patel, M. (2019). Excipients in nasal drug delivery: A review. Current Drug Delivery, 16(6), 888-898.
5. US FDA Center for Drug Evaluation and Research. (2021). Chemical and Biological Documentation for Nasal Products.